People with systemic lupus erythematosus (SLE) who have been in remission for at least a year and take low-dose…
Articles by Margarida Azevedo
PRV-3279, a potential therapy for people with systemic lupus erythematosus (SLE), durably blocks B-cells to prevent them from producing damaging antibodies,…
Researchers investigated health care use by people with systemic lupus erythematosus (SLE) and found that patients were more apt to seek clinical care during…
Findings from a large “Treat-to-Target” (T2T) study of systemic lupus erythematosus (SLE), focusing on patient and disease characteristics, and factors influencing a…
Researchers developed a new monoclonal antibody against specific cells and molecules involved in systemic lupus erythematosus (SLE) that has shown…
Mallinckrodt Pharmaceuticals announced the results of three retrospective analyses that studied H.P. Acthar Gel in three distinct patient populations…
Researchers have identified a key molecular pathway that drives the maturation of antibody-producing B-cells, capable of weeding out harmful pathogens. The discovery may…
Salk Institute researchers have shown how FDA-approved rapamycin might have an additional therapeutic effect due to its ability to target the neural…
Corbus Pharmaceuticals announced the addition of a protocol amendment to one of the company’s existing Investigational New Drug (IND) Applications…
In a landmark study, principal researcher Virginia Pascual at the Baylor Institute for Immunology Research, and colleagues, investigated the molecular diversity of lupus…